2026-01-27 - Analysis Report
# Abbott Laboratories (ABT) Analysis Report

## Company Overview
Abbott Labs is a multinational healthcare company.

## Return Rate Comparison
- Rate (ABT): 55.81%
- Rate_vs (VOO): 127.58%
- Divergence: 0.72 (max: 72.30, min: -72.50, current: -72.50)
- Relative divergence: 0.00%

## Alpha, Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 54.0% | 11.7% | 45.0% | 1.1 | 125.9B |
| 2017-2019  | 64.0% | 11.7% | 39.0% | 1.0 | 151.2B |
| 2018-2020  | 51.0% | 29.7% | 27.0% | 0.9 | 190.6B |
| 2019-2021  | 76.0% | 29.7% | 12.0% | 0.8 | 244.9B |
| 2020-2022  | 0.0% | 28.9% | -4.0% | 0.8 | 191.1B |
| 2021-2023  | -56.0% | 26.1% | -74.0% | 0.7 | 191.6B |
| 2022-2024  | -43.0% | 21.3% | -72.0% | 0.7 | 196.9B |
| 2023-2025  | 7.0% | 19.0% | -69.0% | 0.3 | 218.1B |

## Stock Price Fluctuations
- Close: $108.77
- Last-market: $1.26 (1.26)
- 5-day SMA: $113.33
- 20-day SMA: $122.20
- 60-day SMA: $124.78

## RSI, PPO Index Indicators
- Market Risk Indicator (MRI): 0.70
- RSI: 13.83
- PPO: -1.59
- Buy (Cash 0%)
- Risk Level: Medium (MRI 0.70)
- Recent (20 days) relative divergence change: worsening
- 7-day Rank change: up
- 7-day Dynamic Expected Return change: improving
- Expected Return (%): -88.42%
- Expected excess return compared to S&P 500 if invested long-term: more than 2 years

## Recent News & Significant Events
- Insider Purchase: CHAIRMAN AND CEO bought 18,800 shares
- Abbott Reworks Nutrition While Targeting Cancer Diagnostics With Exact Sciences Deal
- Evercore ISI Says Abbottâ€™s (ABT) Core Growth Drivers Are Still Intact
- Abbott Dives 7% On Quarterly Upset As Exact Close Looms
- Is The Fall In Abbott Stock Justified?
- Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

## Analyst Opinions
- Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.76 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): $136.47 / $169.00 / $115.00

## Recent Earnings Analysis
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2025-10-29 | 0.94 | 10.63 B$ |
- Quarterly EPS and Revenue have been steadily decreasing.

## Financial Information
### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | 11.37B | 55.36% |
| 2025-06-30 | 11.14B | 56.44% |
| 2025-03-31 | 10.36B | 56.86% |
| 2024-12-31 | 10.97B | 54.97% |
- Revenue has been steadily decreasing.

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | 50.95B | 3.23% |
| 2025-06-30 | 50.56B | 3.52% |
| 2025-03-31 | 48.81B | 2.71% |
| 2024-12-31 | 47.66B | 19.36% |
- Equity and ROE have been fluctuating.

## Comprehensive Analysis
- ABT has had a significant drop in performance compared to VOO.
- Alpha, Beta analysis shows a fluctuating trend.
- Stock price fluctuations have been decreasing.
- RSI, PPO Index Indicators show a risk level of Medium.
- Recent news and significant events indicate potential challenges for the company.
- Analyst opinions are generally positive.
- Earnings analysis shows a steady decrease in EPS and Revenue.
- Financial information shows a fluctuating equity and ROE.
- Overall, ABT's performance has been negative in recent times.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.